Positive preclinical data in foetal growth restriction with new Ark gene therapy
This article was originally published in Scrip
Executive Summary
Data from a number of preclinical collaborative research programmes using Ark Therapeutics' EG013, an adenoviral vector containing a vascular endothelial growth factor (VEGF) gene, suggest it has promise in the treatment of foetal growth restriction (FGR) during pregnancy.